Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranitidine duty suspension

Executive Summary

Subject of Sept. 24 hearing by Ways & Means/Trade Subcommittee will be legislation (HR 3130) temporarily suspending duty on ranitidine hydrochloride, the active ingredient in Glaxo's Zantac. Witnesses will include Glaxo and SmithKline Beecham. Glaxo maintains that the duty suspension would result in loss of Treasury revenues of $7-$9 mil. per year, based on CBO figures.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts